Immutep's Efti In Combination With MSD's KEYTRUDA Leads To Efficacy With Favourable Safety In First Line Head And Neck Cancer
Portfolio Pulse from Benzinga Newsdesk
Immutep's Efti combined with MSD's KEYTRUDA shows promising efficacy and safety in first-line head and neck cancer treatment, with significant results presented at ESMO Congress 2024. The combination demonstrated a higher objective response rate and durability compared to KEYTRUDA alone.
September 16, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immutep's Efti, in combination with KEYTRUDA, shows promising results in head and neck cancer, with higher response rates and durability. This could enhance Immutep's market position and lead to regulatory discussions.
The positive results of Efti in combination with KEYTRUDA in a significant cancer treatment area could lead to increased investor interest and potential regulatory approval, positively impacting Immutep's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
MSD's KEYTRUDA, when combined with Immutep's Efti, shows improved efficacy in head and neck cancer. This could reinforce KEYTRUDA's position in the oncology market.
The combination of KEYTRUDA with Efti showing improved results could enhance KEYTRUDA's market position, potentially benefiting Merck's stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70